4.5 Article

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

Journal

CANCER SCIENCE
Volume 105, Issue 7, Pages 795-801

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cas.12430

Keywords

Apoptosis; KPT-SINE; mantle cell lymphoma; p53; XPO1

Categories

Funding

  1. National Institutes of Health Lymphoma SPORE [CA136411, P50CA136411]
  2. Leukemia SPORE [CA100632]
  3. P01 The Therapy of AML [CA55164]
  4. Cancer Center Support Grant [CA16672]
  5. Paul and Mary Haas Chair in Genetics
  6. Osaka Cancer Research Foundation
  7. Japan Leukemia Research Fund
  8. Ministry of Education, Culture, Sports, Science and Technology in Japan
  9. Fredrick B. Hagemeister Research Fund
  10. Grants-in-Aid for Scientific Research [24501306] Funding Source: KAKEN

Ask authors/readers for more resources

The nuclear transporter exportin-1 (XPO1) is highly expressed in mantle cell lymphoma (MCL) cells, and is believed to be associated with the pathogenesis of this disease. XPO1-selective inhibitors of nuclear export (SINE) compounds have been shown to induce apoptosis in MCL cells. Given that p53 is a cargo protein of XPO1, we sought to determine the significance of p53 activation through XPO1 inhibition in SINE-induced apoptosis of MCL cells. We investigated the prognostic impact of XPO1 expression in MCL cells using Oncomine analysis. The significance of p53 mutational/functional status on sensitivity to XPO1 inhibition in cell models and primary MCL samples, and the functional role of p53-mediated apoptosis signaling, were also examined. Increased XPO1 expression was associated with poor prognosis in MCL patients. The XPO1 inhibitor KPT-185 induced apoptosis in MCL cells through p53-dependent and -independent mechanisms, and p53 status was a critical determinant of its apoptosis induction. The KPT-185-induced, p53-mediated apoptosis in the MCL cells occurred in a transcription-dependent manner. Exportin-1 appears to influence patient survival in MCL, and the SINE XPO1 antagonist KPT-185 effectively activates p53-mediated transcription and apoptosis, which would provide a novel strategy for the therapy of MCL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available